Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)

This study has been completed.
Sponsor:
Collaborators:
Eli Lilly and Company
Sanofi
Bristol-Myers-Squibb/Astra-Zeneca
DexCom, Inc.
Bayer
Becton, Dickinson and Company
Medicomp
University of Texas
Biomedical Research Institute of New Mexico
Information provided by (Responsible Party):
Jeff Probstfield, University of Washington
ClinicalTrials.gov Identifier:
NCT01524705
First received: January 17, 2012
Last updated: September 16, 2014
Last verified: September 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2014
  Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)